Abstract
Compared to other monoamine neurotransmitters, information on the association between the histaminergic system and neuropsychiatric disorders is scarce, resulting in a lack of histamine-related treatment for these disorders. The current chapter tries to combine information obtained from genetic studies, neuroimaging, post-mortem human brain studies and cerebrospinal fluid measurements with data from recent clinical trials on histamine receptor agonists and antagonists, with a view to determining the possible role of the histaminergic system in neuropsychiatric disorders and to pave the way for novel histamine-related therapeutic strategies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer’s disease
- CSF:
-
Cerebrospinal fluid
- H1–4R:
-
Histamine 1–4 receptors
- HDC:
-
l-Histidine decarboxylase
- HMT:
-
Histamine N-methyltransferase
- mRNA:
-
Messenger RNA
- PD:
-
Parkinson’s disease
- t-MeHA:
-
Tele-Methylhistamine
- TMN:
-
Tuberomamillary nucleus
References
Agundez JA, Luengo A, Herraez O, Martinez C, Alonso-Navarro H, Jimenez-Jimenez FJ, Garcia-Martin E (2008) Nonsynonymous polymorphisms of histamine-metabolising enzymes in patients with Parkinson’s disease. Neuromolecular Med 10:10–16
Anichtchik OV, Rinne JO, Kalimo H, Panula P (2000) An altered histaminergic innervation of the substantia nigra in Parkinson’s disease. Exp Neurol 163:20–30
Beermann S, Seifert R, Neumann D (2012) Commercially available antibodies against human and murine histamine H(4)-receptor lack specificity. Naunyn Schmiedebergs Arch Pharmacol 385:125–135
Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD (2011) Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease. J Pharmacol Exp Ther 336:38–46
Canellas F, Lin L, Julia MR, Clemente A, Vives-Bauza C, Ollila HM, Hong SC, Arboleya SM, Einen MA, Faraco J, Fernandez-Vina M, Mignot E (2014) Dual cases of type 1 narcolepsy with schizophrenia and other psychotic disorders. J Clin Sleep Med 10:1011–1018
Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389
Castellan Baldan L, Williams KA, Gallezot JD, Pogorelov V, Rapanelli M, Crowley M, Anderson GM, Loring E, Gorczyca R, Billingslea E, Wasylink S, Panza KE, Ercan-Sencicek AG, Krusong K, Leventhal BL, Ohtsu H, Bloch MH, Hughes ZA, Krystal JH, Mayes L, de Araujo I, Ding YS, State MW, Pittenger C (2014) Histidine decarboxylase deficiency causes tourette syndrome: parallel findings in humans and mice. Neuron 81:77–90
Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, Fitch TE, Nakazato M, Hammer RE, Saper CB, Yanagisawa M (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437–451
Chen MH, Bai YM, Chen YS, Huang KL, Hsu JW, Su TP (2014) Comorbidity of narcolepsy and schizophrenia in an adolescent patient. J Chin Med Assoc 77:598–600
Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RL, Lees G, Chazot PL (2009) The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol 157:55–63
Correa BB, Xavier M, Guimaraes J (2006) Association of Huntington’s disease and schizophrenia-like psychosis in a Huntington’s disease pedigree. Clin Pract Epidemiol Ment Health 2:1
Dauvilliers Y, Bassetti C, Lammers GJ, Arnulf I, Mayer G, Rodenbeck A, Lehert P, Ding CL, Lecomte JM, Schwartz JC (2013) Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol 12:1068–1075
Douglass AB, Hays P, Pazderka F, Russell JM (1991) Florid refractory schizophrenias that turn out to be treatable variants of HLA-associated narcolepsy. J Nerv Ment Dis 179:12–17. discussion 18
Douglass AB, Shipley JE, Haines RF, Scholten RC, Dudley E, Tapp A (1993) Schizophrenia, narcolepsy, and HLA-DR15, DQ6. Biol Psychiatry 34:773–780
Egan M, Yaari R, Liu L, Ryan M, Peng Y, Lines C, Michelson D (2012) Pilot randomized controlled study of a histamine receptor inverse agonist in the symptomatic treatment of AD. Curr Alzheimer Res 9:481–490
Egan MF, Zhao X, Gottwald R, Harper-Mozley L, Zhang Y, Snavely D, Lines C, Michelson D (2013) Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia. Schizophr Res 146:224–230
Ercan-Sencicek AG, Stillman AA, Ghosh AK, Bilguvar K, O’Roak BJ, Mason CE, Abbott T, Gupta A, King RA, Pauls DL, Tischfield JA, Heiman GA, Singer HS, Gilbert DL, Hoekstra PJ, Morgan TM, Loring E, Yasuno K, Fernandez T, Sanders S, Louvi A, Cho JH, Mane S, Colangelo CM, Biederer T, Lifton RP, Gunel M, State MW (2010) L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med 362:1901–1908
Feliszek M, Speckmann V, Schacht D, von Lehe M, Stark H, Schlicker E (2015) A search for functional histamine H4 receptors in the human, guinea pig and mouse brain. Naunyn Schmiedebergs Arch Pharmacol 388:11–17
Fernandez-Guasti A, Kruijver FP, Fodor M, Swaab DF (2000) Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol 425:422–435
Fortuyn HA, Lappenschaar GA, Nienhuis FJ, Furer JW, Hodiamont PP, Rijnders CA, Lammers GJ, Renier WO, Buitelaar JK, Overeem S (2009) Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry 31:146–154
Galeotti N, Sanna MD, Ghelardini C (2013) Pleiotropic effect of histamine H4 receptor modulation in the central nervous system. Neuropharmacology 71:141–147
Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, Lovenberg TW (2009) JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 56:1131–1137
Garbarg M, Javoy-Agid F, Schwartz JC, Agid Y (1983) Brain histidine decarboxylase activity in Parkinson’s disease. Lancet 1:74–75
Giannoni P, Medhurst AD, Passani MB, Giovannini MG, Ballini C, Corte LD, Blandina P (2010) Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-p yridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther 332:164–172
Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res 11:47–58
Haas H, Panula P (2003) The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev 4:121–130
Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183–1241
Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA (2014) A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia. Schizophr Bull 40:1433–1442
Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, Sakurai T (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345–354
Heidari A, Tongsook C, Najafipour R, Musante L, Vasli N, Garshasbi M, Hu H, Mittal K, McNaughton AJ, Sritharan K, Hudson M, Stehr H, Talebi S, Moradi M, Darvish H, Arshad Rafiq M, Mozhdehipanah H, Rashidinejad A, Samiei S, Ghadami M, Windpassinger C, Gillessen-Kaesbach G, Tzschach A, Ahmed I, Mikhailov A, Stavropoulos DJ, Carter MT, Keshavarz S, Ayub M, Najmabadi H, Liu X, Ropers HH, Macheroux P, Vincent JB (2015) Mutations in the histamine N-methyltransferase gene, HNMT, are associated with nonsyndromic autosomal recessive intellectual disability. Hum Mol Genet 24:5697–5710
Higuchi M, Yanai K, Okamura N, Meguro K, Arai H, Itoh M, Iwata R, Ido T, Watanabe T, Sasaki H (2000) Histamine H(1) receptors in patients with Alzheimer’s disease assessed by positron emission tomography. Neuroscience 99:721–729
Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 334:345–348
Homberg JR, van den Hove DL (2012) The serotonin transporter gene and functional and pathological adaptation to environmental variation across the life span. Prog Neurobiol 99:117–127
Horton JR, Sawada K, Nishibori M, Zhang X, Cheng X (2001) Two polymorphic forms of human histamine methyltransferase: structural, thermal, and kinetic comparisons. Structure 9:837–849
Howland RH (1997) Sleep-onset rapid eye movement periods in neuropsychiatric disorders: implications for the pathophysiology of psychosis. J Nerv Ment Dis 185:730–738
Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimao R, Lin JS, Franco P (2012) Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 35:55–60
Ito C, Morisset S, Krebs MO, Olie JP, Loo H, Poirier MF, Lannfelt L, Schwartz JC, Arrang JM (2000) Histamine H2 receptor gene variants: lack of association with schizophrenia. Mol Psychiatry 5:159–164
Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, Lieberman JA, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykamian MA (2015) A Phase II study of a histamine H(3) receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophr Res 164:136–142
Jimenez-Jimenez FJ, Alonso-Navarro H, Garcia-Martin E, Agundez JA (2016) Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore) 95:e4147
John J, Thannickal TC, McGregor R, Ramanathan L, Ohtsu H, Nishino S, Sakai N, Yamanaka A, Stone C, Cornford M, Siegel JM (2013) Greatly increased numbers of histamine cells in human narcolepsy with cataplexy. Ann Neurol 74:786–793
Kaminsky R, Moriarty TM, Bodine J, Wolf DE, Davidson M (1990) Effect of famotidine on deficit symptoms of schizophrenia. Lancet 335:1351–1352
Kano M, Fukudo S, Tashiro A, Utsumi A, Tamura D, Itoh M, Iwata R, Tashiro M, Mochizuki H, Funaki Y, Kato M, Hongo M, Yanai K (2004) Decreased histamine H1 receptor binding in the brain of depressed patients. Eur J Neurosci 20:803–810
Karlstedt K, Jin C, Panula P (2013) Expression of histamine receptor genes Hrh3 and Hrh4 in rat brain endothelial cells. Br J Pharmacol 170:58–66
Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, Lozano AM (2011) Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry 168:502–510
Kishi T, Iwata N (2015) Efficacy and tolerability of histamine-2 receptor antagonist adjunction of antipsychotic treatment in Schizophrenia: a meta-analysis of randomized placebo-controlled trials. Pharmacopsychiatry 48:30–36
Krystal AD (2009) A compendium of placebo-controlled trials of the risks/benefits of pharmacological treatments for insomnia: the empirical basis for U.S. clinical practice. Sleep Med Rev 13:265–274
Krystal AD, Richelson E, Roth T (2013) Review of the histamine system and the clinical effects of H1 antagonists: basis for a new model for understanding the effects of insomnia medications. Sleep Med Rev 17:263–272
Kubo M, Kishi T, Matsunaga S, Iwata N (2015) Histamine H3 receptor antagonists for Alzheimer’s disease: a systematic review and meta-analysis of randomized placebo-controlled trials. J Alzheimers Dis 48:667–671
Ledesma MC, Garcia-Martin E, Alonso-Navarro H, Martinez C, Jimenez-Jimenez FJ, Benito-Leon J, Puertas I, Rubio L, Lopez-Alburquerque T, Agundez JA (2008) The nonsynonymous Thr105Ile polymorphism of the histamine N-methyltransferase is associated to the risk of developing essential tremor. Neuromolecular Med 10:356–361
Leu-Semenescu S, De Cock VC, Le Masson VD, Debs R, Lavault S, Roze E, Vidailhet M, Arnulf I (2011) Hallucinations in narcolepsy with and without cataplexy: contrasts with Parkinson’s disease. Sleep Med 12:497–504
Lieberman P (2009) Histamine, antihistamines, and the central nervous system. Allergy Asthma Proc 30:482–486
Lin JS (2000) Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons. Sleep Med Rev 4:471–503
Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin−/− mice and patients. Neurobiol Dis 30:74–83
Liu CQ, Chen Z, Liu FX, Hu DN, Luo JH (2007) Involvement of brain endogenous histamine in the degeneration of dopaminergic neurons in 6-hydroxydopamine-lesioned rats. Neuropharmacology 53:832–841
Liu CQ, Shan L, Balesar R, Luchetti S, Van Heerikhuize JJ, Luo JH, Swaab DF, Bao AM (2010) A quantitative in situ hybridization protocol for formalin-fixed paraffin-embedded archival post-mortem human brain tissue. Methods 52:359–366
Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA (2000) Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843
Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45:651–660
Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321:1032–1045
Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J (2013) A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. J Clin Psychopharmacol 33:472–478
Mizuguchi H, Yabumoto M, Imamura I, Fukui H, Wada H (1990) Immuno-cross-reactivity of histidine and dopa decarboxylases. Biochem Biophys Res Commun 173:1299–1303
Monczor F, Copsel S, Fernandez N, Davio C, Shayo C (2017) Histamine H2-receptor in blood cells: a suitable target for the treatment of acute myeloid leukemia. Handb Exp Pharmacol. doi: 10.1007/164_2016_8
Motawaj M, Peoc’h K, Callebert J, Arrang JM (2010) CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer’s disease. J Alzheimers Dis 22:861–871
Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T, Tanaka C (1991) Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30:349–356
Nakamura S, Ohnishi K, Nishimura M, Suenaga T, Akiguchi I, Kimura J, Kimura T (1996) Large neurons in the tuberomammillary nucleus in patients with Parkinson’s disease and multiple system atrophy. Neurology 46:1693–1696
Neumann D (2017) Role of the histamine H4-receptor in bronchial asthma. Handb Exp Pharmacol. doi: 10.1007/164_2016_11
Orange PR, Heath PR, Wright SR, Ramchand CN, Kolkeiwicz L, Pearson RC (1996) Individuals with schizophrenia have an increased incidence of the H2R649G allele for the histamine H2 receptor gene. Mol Psychiatry 1:466–469
Overeem S, Mignot E, van Dijk JG, Lammers GJ (2001) Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 18:78–105
Oyewumi LK, Vollick D, Merskey H, Plumb C (1994) Famotidine as an adjunct treatment of resistant schizophrenia. J Psychiatry Neurosci 19:145–150
Palada V, Terzic J, Mazzulli J, Bwala G, Hagenah J, Peterlin B, Hung AY, Klein C, Krainc D (2012) Histamine N-methyltransferase Thr105Ile polymorphism is associated with Parkinson’s disease. Neurobiol Aging 33(836):e831–e833
Pang YP, Zheng XE, Weinshilboum RM (2001) Theoretical 3D model of histamine N-methyltransferase: insights into the effects of a genetic polymorphism on enzymatic activity and thermal stability. Biochem Biophys Res Commun 287:204–208
Panula P, Nuutinen S (2013) The histaminergic network in the brain: basic organization and role in disease. Nat Rev 14:472–487
Panula P, Chazot PL, Cowart M, Gutzmer R, Leurs R, Liu WL, Stark H, Thurmond RL, Haas HL (2015) International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors. Pharmacol Rev 67:601–655
Passani MB, Blandina P (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci 32:242–249
Perry E, Court J, Goodchild R, Griffiths M, Jaros E, Johnson M, Lloyd S, Piggott M, Spurden D, Ballard C, McKeith I, Perry R (1998) Clinical neurochemistry: developments in dementia research based on brain bank material. J Neural Transm 105:915–933
Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, Li R, Hungs M, Pedrazzoli M, Padigaru M, Kucherlapati M, Fan J, Maki R, Lammers GJ, Bouras C, Kucherlapati R, Nishino S, Mignot E (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6:991–997
Pittenger C (2017) Histamine decarboxylase deficiency as a cause for Tourette syndrome. Handb Exp Pharmacol. doi: 10.1007/164_2016_127
Plazzi G, Fabbri C, Pizza F, Serretti A (2015) Schizophrenia-like symptoms in narcolepsy type 1: shared and distinctive clinical characteristics. Neuropsychobiology 71:218–224
Prell GD, Green JP (1991) Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Suppl 33:343–363
Prell GD, Khandelwal JK, Burns RS, Blandina P, Morrishow AM, Green JP (1991) Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson’s disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice. J Neural Transm 3:109–125
Preuss CV, Wood TC, Szumlanski CL, Raftogianis RB, Otterness DM, Girard B, Scott MC, Weinshilboum RM (1998) Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol 53:708–717
Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, Roytta M, Panula P (2002) Increased brain histamine levels in Parkinson’s disease but not in multiple system atrophy. J Neurochem 81:954–960
Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, Wyatt RJ, Deutsch SI (1996) An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 19:341–348
Roth T, Rogowski R, Hull S, Schwartz H, Koshorek G, Corser B, Seiden D, Lankford A (2007) Efficacy and safety of doxepin 1 mg, 3 mg, and 6 mg in adults with primary insomnia. Sleep 30:1555–1561
Rutherford K, Parson WW, Daggett V (2008) The histamine N-methyltransferase T105I polymorphism affects active site structure and dynamics. Biochemistry 47:893–901
Sanna MD, Ghelardini C, Thurmond RL, Masini E, Galeotti N (2017) Behavioural phenotype of histamine H4 receptor knockout mice: focus on central neuronal functions. Neuropharmacology 114:48–57
Schlicker E, Kathmann M (2017) Role of the histamine H3-receptor in the central nervous system. Handb Exp Pharmacol. doi: 10.1007/164_2016_12
Schneider EH, Seifert R (2016) The histamine H-receptor and the central and peripheral nervous system: a critical analysis of the literature. Neuropharmacology 106:116–128
Schneider EH, Neumann D, Seifert R (2014a) Modulation of behavior by the histaminergic system: lessons from H(1)R-and H(2)R-deficient mice. Neurosci Biobehav Rev 42:252–266
Schneider EH, Neumann D, Seifert R (2014b) Modulation of behavior by the histaminergic system: lessons from HDC-, H3R- and H4R-deficient mice. Neurosci Biobehav Rev 47:101–121
Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot PL, Bao AM, Swaab DF (2012a) Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson’s patients: a postmortem study. Neurobiol Aging 33(1488):e1481–e1413
Shan L, Bossers K, Unmehopa U, Bao AM, Swaab DF (2012b) Alterations in the histaminergic system in Alzheimer’s disease: a postmortem study. Neurobiol Aging 33:2585–2598
Shan L, Hofman MA, van Wamelen DJ, Van Someren EJ, Bao AM, Swaab Dick F (2012c) Diurnal fluctuation in histidine decarboxylase expression, the rate limiting enzyme for histamine production, and its disorder in neurodegenerative diseases. Sleep 35:713–715
Shan L, Liu CQ, Balesar R, Hofman MA, Bao AM, Swaab DF (2012d) Neuronal histamine production remains unaltered in Parkinson’s disease despite the accumulation of Lewy bodies and Lewy neurites in the tuberomamillary nucleus. Neurobiol Aging 33:1343–1344
Shan L, Qi XR, Balesar R, Swaab DF, Bao AM (2013a) Unaltered histaminergic system in depression: a postmortem study. J Affect Disord 146:220–223
Shan L, Swaab DF, Bao AM (2013b) Neuronal histaminergic system in aging and age-related neurodegenerative disorders. Exp Gerontol 48:603–607
Shan L, Schipper P, Nonkes LJ, Homberg JR (2014) Impaired fear extinction as displayed by serotonin transporter knockout rats housed in open cages is disrupted by IVC cage housing. PLoS One 9:e91472
Shan L, Bao AM, Swaab DF (2015a) The human histaminergic system in neuropsychiatric disorders. Trends Neurosci 38:167–177
Shan L, Dauvilliers Y, Siegel JM (2015b) Interactions of the histamine and hypocretin systems in CNS disorders. Nat Rev Neurol 11:401–413
Shiroshi M, Kobayashi T (2017) Structural analysis of the histamine H1-receptor. Handb Exp Pharmacol. doi: 10.1007/164_2016_10
Tabuchi S, Tsunematsu T, Black SW, Tominaga M, Maruyama M, Takagi K, Minokoshi Y, Sakurai T, Kilduff TS, Yamanaka A (2014) Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function. J Neurosci 34:6495–6509
Talih FR (2011) Narcolepsy presenting as schizophrenia: a literature review and two case reports. Innov Clin Neurosci 8:30–34
Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, Cornford M, Siegel JM (2000) Reduced number of hypocretin neurons in human narcolepsy. Neuron 27:469–474
Tongsook C, Niederhauser J, Kronegger E, Straganz G, Macheroux P (2016) Leucine 208 in human histamine N-methyltransferase emerges as a hotspot for protein stability rationalizing the role of the L208P variant in intellectual disability. Biochim Biophys Acta 1863:188–199
Tsuang D, DiGiacomo L, Lipe H, Bird TD (1998) Familial aggregation of schizophrenia-like symptoms in Huntington’s disease. Am J Med Genet 81:323–327
Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD (2000) Familial aggregation of psychotic symptoms in Huntington’s disease. Am J Psychiatry 157:1955–1959
Valko PO, Gavrilov YV, Yamamoto M, Reddy H, Haybaeck J, Mignot E, Baumann CR, Scammell TE (2013) Increase of histaminergic tuberomammillary neurons in narcolepsy. Ann Neurol 74:794–804
van Wamelen DJ, Shan L, Aziz NA, Anink JJ, Bao AM, Roos RA, Swaab DF (2011) Functional increase of brain histaminergic signaling in Huntington’s disease. Brain Pathol 21:419–427
Vizuete ML, Merino M, Venero JL, Santiago M, Cano J, Machado A (2000) Histamine infusion induces a selective dopaminergic neuronal death along with an inflammatory reaction in rat substantia nigra. J Neurochem 75:540–552
Yanai K, Tashiro M (2007) The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 113:1–15
Yang X, Liu C, Zhang J, Han H, Wang X, Liu Z, Xu Y (2015) Association of histamine N-methyltransferase Thr105Ile polymorphism with Parkinson’s disease and schizophrenia in Han Chinese: a case-control study. PLoS One 10:e0119692
Yu X, Zecharia A, Zhang Z, Yang Q, Yustos R, Jager P, Vyssotski AL, Maywood ES, Chesham JE, Ma Y, Brickley SG, Hastings MH, Franks NP, Wisden W (2014) Circadian factor BMAL1 in histaminergic neurons regulates sleep architecture. Curr Biol 24:2838–2844
Acknowledgements
Original research supported by the China Scholarship Council for State Scholarship Fund [grant number (2007) 3020] to Dr. Ling Shan and the China programme of introducing talents of discipline to universities (B13026) to Prof Ai-min Bao and Prof Dick F. Swaab. The work has been awarded a Young Investigators Award by the European histamine research society to Dr. Ling Shan who currently supported by a 2014 NARSAD Young Investigator Grant from the Brain & Behavior Research Foundation. The authors are also grateful to the Netherlands Brain Bank (Director Dr. Inge Huitinga) for providing human brain material and clinical details, and to Mrs. W.T.P. Verweij for secretarial assistance.
Conflicts of Interest: We declare that we have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Shan, L., Bao, AM., Swaab, D.F. (2017). Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders. In: Hattori, Y., Seifert, R. (eds) Histamine and Histamine Receptors in Health and Disease. Handbook of Experimental Pharmacology, vol 241. Springer, Cham. https://doi.org/10.1007/164_2016_125
Download citation
DOI: https://doi.org/10.1007/164_2016_125
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-58192-7
Online ISBN: 978-3-319-58194-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)